Consistent with this hypothesis, we have previously found that SIINFEKL-specific CD8+ T cells are present in untreated, intracerebrally implanted B16 melanoma tumors expressing ovalbumin (B16OVA)26, but a vaccine composed of SIINFEKL conjoined to P30 (SIINFEKL-P30) is ineffective, on its own, against intracerebral B16OVA tumors—analogous to our findings with the Odc1 neoantigen in SMA560. This evidence concerns the gene CD8A and melanoma.